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An Examination of Trans Fat Labeling: 
Splitting the Third & Ninth Circuit 
Jack Gainey* 
Abstract 
At first glance, consumer claims alleging misleading labeling 
would seem to find a simple resolution. Under 21 U.S.C. § 343, 
which governs misbranded food, a food product is misbranded if 
“its labeling is false or misleading.”1 However, controversial 
interpretation of seemingly straightforward statutory language, 
together with evolving case law, have blurred a once clear picture. 
Disagreement over the federal preemption of consumer claims 
regarding trans fat, underscored by a dispute regarding standing, 
have combined to create a divergence of opinions between courts 
across the country.  
In 2011, the United States District Court for the Northern 
District of California considered a class action trans fat 
misbranding claim alleging that a food manufacturer had 
deceptively labeled certain ice cream products as containing zero 
grams of trans fat even though the products contained partially 
hydrogenated oil, a source of trans fat.2 The district court found 
that the class of consumers had standing to bring a trans fat 
misbranding claim.3 However, the district court ultimately 
dismissed the case, holding that the trans fat misbranding claims 
were preempted by federal law.4 The Ninth Circuit Court of Appeals 
later affirmed the district court’s dismissal on federal preemption 
grounds.5 In 2015, the Ninth Circuit returned to the issue in a 
                                                                                                     
 * Candidate for J.D., May 2017, Washington and Lee University School of 
Law. 
 1. 21 U.S.C. § 343(a)(1) (2017). 
 2. Carrea v. Dreyer’s Grand Ice Cream, Inc., No. C 10-01044 JSW, 2011 WL 
159380, at *1 (N.D. Cal. Jan. 10, 2011). 
 3. Id. at *2–*3.  
 4. Id. at *4. 
 5. Carrea v. Dreyer’s Grand Ice Cream, Inc., 475 Fed. App’x 113, 115 (9th 
Cir. 2012). 
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different case, but this time it reached the opposite conclusion, 
holding that claims by consumers alleging that a “No Trans Fat” 
label was misleading as applied to a product containing partially-
hydrogenated oil were not preempted by federal law.6  
The Third Circuit on the other hand, dismissed a similar 
consumer protection claim.7 In Young, products that contained 
trans fat but stated, “NO TRANS FAT, directly above a symbol of a 
heart to convey heart health” were found not to be misleading.8 The 
Third Circuit pronounced that the consumer’s claims were 
contradicted by both FDA regulations governing trans fats, as well 
as disclosures made on the product’s own packaging.9 The FDA 
requires that fat levels of less than 0.5 grams per serving shall be 
expressed as zero.10 Thus, the Third Circuit determined that 
because the product in question contained less than 0.5 grams of 
trans fat per serving, the manufacturer’s “claims that [their 
product] contains ‘NO TRANS FAT’ and ‘No Trans Fatty Acids’ 
[were] consistent with FDA regulations.”11  
The part of the label, and the substance that courts choose 
to apply the FDA regulation to, drastically changes the meaning 
and impact of the regulation. The Ninth Circuit’s interpretation is 
supported by logic and a greater weight of evidence. Warning letters 
issued by the FDA, overturned cases relied on by the Third Circuit, 
and the structure and text of the regulations all reinforce the Ninth 
Circuit’s decision. 
  
                                                                                                     
 6. See Reid v. Johnson & Johnson, 780 F.3d 952, 959–63 (9th Cir. 2015) 
(considering whether a plaintiff’s claim that a “No Trans Fat” label was 
misleading as used to describe a product containing partially-hydrogenated 
vegetable oil, which contains trans fats, was preempted under federal law). 
 7. See Young v. Johnson & Johnson, No. CIV.A. 11-4580 JAP, 2012 WL 
1372286, at *1 (D.N.J. Apr. 19, 2012) (discussing the granting of Johnson & 
Johnson’s motion to dismiss), aff’d, 525 F. App’x 179 (3d Cir. 2013). 
 8. Id. 
 9. Id. 
 10. 21 C.F.R. § 101.9(c)(2)(ii) (2016). 
 11. See Young, 2012 WL 1372286, at *3–*5 (explaining why Benecol’s claims 
were consistent with FDA regulations). 
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I. Introduction 
Food labeling has seen an increased level of consideration and 
scrutiny due to “dietary-related diseases” and consumer trends 
showing an increased interest in nutrition.12 The Food and Drug 
Administration (FDA) currently has authority over food labeling.13 
The FDA traces its origins to public concern over Upton Sinclair’s 
best-selling novel The Jungle, which exposed unsanitary 
conditions in the American meat-packing industry.14  
The early twentieth century saw an unprecedented expansion 
in the regulation of food safety, which led to many laws aimed at 
protecting consumers.15 Another wave of consumer protection laws 
                                                                                                     
 12. See Jennifer L. Pomeranz, Litigation to Address Misleading Food Label 
Claims and the Role of the State Attorneys General, 26 REGENT U.L. REV. 421, 421 
(2014) (“The increased global prevalence of diet-related diseases, such as diabetes, 
heart disease, and cancer, elevates the importance of truthful and accurate 
nutrition information in the marketplace.”). 
 13. See 21 U.S.C. § 343-1 (2012) (explaining national uniform nutrition 
labeling). 
 14. See generally UPTON SINCLAIR, THE JUNGLE (Dover 2001) (1906). 
 15. See generally Spencer Weber Waller et al., Consumer Protection in the 
United States: An Overview, 2011 EUR. J. OF CONS. L. 803 (2011). 
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were passed in the 1960’s under both President Kennedy and 
President Johnson.16 Complex consumer protection laws now exist 
at both the state and federal level.17  
The duty of protecting consumers is dispersed through 
different channels. Many states charge their attorney generals 
with enforcing their consumer protection laws, while consumers 
have the right to bring common law tort claims, statutory causes 
of action, and class actions.18 The Food, Drug and Cosmetic Act 
(FDCA) empowers the FDA to “protect the public health by 
ensuring that . . . foods are safe, wholesome, sanitary, and properly 
labeled.”19 The FDA’s standard for whether a food product is 
misbranded is if the labeling is “false or misleading in any 
particular.”20 False and deceptive advertising claims are fertile 
ground for consumer protection litigation.21 
Trans fat has become a heavily litigated issue in the realm of 
consumer protection. Consumers claim that manufacturers 
misrepresent their products by deceptively labeling trans fat.22 
Courts have struggled particularly with the statutes and 
regulations that govern the disclosure of trans fat in food 
products.23 These products are required by regulation to have a 
                                                                                                     
 16. See id. (explaining the progression of consumer protection laws). 
 17. See id. (“The result is that American consumers are protected from 
unsafe products, fraud, deceptive advertising, and unfair business practices 
through a mixture of national, state, and local governmental laws and the 
existence of many private rights of actions.”). 
 18. See id. (explaining the different private rights of action for consumers). 
 19. What Does FDA Do?, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194877.htm (last visited 
Apr. 18, 2017) (on file with the Washington and Lee Journal of Civil Rights and 
Social Justice). 
 20. 21 U.S.C. § 343(a) (2012). 
 21. See Pomeranz, supra note 12, at 423 (“As a result of outdated regulations 
and lax enforcement, the initiation of private lawsuits has escalated.”). 
 22. See Carrea v. Dreyer’s Grand Ice Cream, Inc., No. C 10-01044 JSW, 2011 
WL 159380, at *1 (N.D. Cal. Jan. 10, 2011) (“Plaintiff . . . [alleges] that the ‘0g 
Trans Fat’ statements displayed on the product packaging and in marketing 
materials are false and misleading as allegedly determined by the FDA”), aff’d, 
475 F. App’x 113 (9th Cir. 2012); Reid v. Johnson & Johnson, 780 F.3d 952, 955–
57 (9th Cir. 2015) (describing the underlying claim by a consumer that a “No 
Trans Fat” label found on a margarine product was unlawfully misleading 
because the product did contain trans fats). 
 23. See Reid, 780 F.3d at 960 (“FDA regulations specifically address trans 
fat. They provide that trans fat should generally be disclosed in the nutrition 
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straightforward statement of the number of grams of trans fat per 
serving.24 However, that same regulation mandates “[t]rans fat 
content shall be indented and expressed as grams per serving to 
the nearest 0.5 (1/2)-gram increment . . . . If the serving contains 
less than 0.5 gram, the content, when declared, shall be expressed 
as zero.”25 The difference in regulations governing claims inside 
the nutrition label, as opposed to nutrient content claims outside 
the label have also caused confusion. 
Consumers across the country have brought class action 
lawsuits against manufacturers alleging their product packaging 
contains misrepresentations. In 2014, The Quaker Oats Company 
paid $1.4 million to settle a class action lawsuit alleging that 
Chewy Granola Bars were “deceptively labeled” as having 0 grams 
of trans fat, but in fact contained the substance.26 About fifty 
different flavors of Quaker products were involved in this class 
action. Quaker also agreed to injunctive relief which removed 
partially hydrogenated oils that contained trans fat from those 
products.27  
Courts have disagreed over whether these consumers have 
standing to sue.28 Other courts that decided these cases on the 
merits, disagreed over whether these claims are preempted or 
not.29 Some courts have denied standing, reasoning that, 
“apprehension about a possible future injury [is] insufficient to 
establish injury-in-fact”30 Other courts have decided that a 
plaintiff’s financial loss in paying more for a supposedly healthy 
product can establish the injury-in-fact element of standing.31  
                                                                                                     
label . . . ” (citing 21 C.F.R. § 101.9(c)(2) (2016))). 
 24. 21 C.F.R. § 101.9(c)(2)(ii) (2016). 
 25. Id. (emphasis added). 
 26. Rose Bouboushian, Quaker Oats to Pay $1.4M to Settle Class Action, 
COURTHOUSE NEWS SERV. (July 31, 2014, 11:48 AM), 
http://www.courthousenews.com/quaker-oats-to-pay-1-4m-to-settle-class-action/ 
(last visited Apr. 18, 2017) (on file with the Washington and Lee Journal of Civil 
Rights and Social Justice). 
 27. Id. 
 28. Young v. Johnson & Johnson, No. CIV.A. 11-4580 JAP, 2012 WL 
1372286, at *3 (D.N.J. Apr. 19, 2012), aff’d, 525 F. App’x 179 (3d Cir. 2013). 
 29. Id. 
 30. Id. 
 31. See Askin v. Quaker Oats Co., 818 F. Supp. 2d 1081, 1084 (N.D. Ill. 2011) 
(“[M]embers of the class did not suffer physical injury, but it does not mean that 
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On the preemption issue, some courts have decided these 
claims are preempted because the manufacturer statements 
complied with FDA regulations.32 Other courts have decided that 
because the FDA extends specific preemption protections to claims 
about fat, and those protections were specifically not extended to 
trans fats, it would be “incongruous” for the FDA regulations to 
preempt trans fat claims.33 
The Third Circuit and the Ninth Circuit have come to different 
conclusions on whether consumer claims regarding trans fat 
labeling should be preempted or allowed.34 That circuit split, and 
other similar cases will be explored below en route to a proposed 
answer to the question of whether these consumer claims 
regarding trans fat labeling should be preempted.35  
Section II(a) will outline what trans fats are and the impact 
they have. Section II(b) offers an in depth look at the statutory 
background involved in these consumer protection issues. Section 
II(c) discusses the federal preemption of labeling regulations. 
Section III(a) examines how the Ninth Circuit originally decided 
these claims were preempted, and then recently reversed that 
decision. Section III(b) scrutinizes the Third Circuit’s decision that 
consumer claims regarding trans fat labeling should be preempted. 
Section III(c) analyzes how other courts outside of the Third and 
Ninth have dealt with similar issues. Finally, Section IV will 
conclude this examination with a resolution to this complex issue.  
                                                                                                     
they were uninjured. The plaintiffs’ loss is financial: they paid more for the toys 
than they would have, had they known of the risks the beads posed to children. A 
financial injury creates standing.”). 
 32. Carrea v. Dreyer’s Grand Ice Cream, Inc., No. C 10-01044 JSW, 2011 WL 
159380, at *3 (N.D. Cal. Jan. 10, 2011). 
 33. See, e.g., Reid v. Johnson & Johnson, 780 F.3d 952, 962–63 (9th Cir. 
2015) (explaining that interpreting FDA regulations to allow “No Trans Fat” 
labelling, despite a lack of scientific consensus on the dangers of trans fat, would 
not be consistent with other similar labelling restrictions). 
 34. See generally id.; Young v. Johnson & Johnson, No. CIV.A. 11-4580 JAP, 
2012 WL 1372286, at *3 (D.N.J. Apr. 19, 2012) aff’d, 525 F. App’x 179 (3d Cir. 
2013). 
 35. Id. 
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II. Background 
A. Trans Fat and its Impact 
Trans Fats “are formed during the partial hydrogenation of 
vegetable oils, a process that converts vegetable oils into semi-solid 
fats for use in margarines, commercial cooking and manufacturing 
processes.”36 Food producers have increasingly used trans fat over 
the last fifteen years due to its cost effective nature37 and long shelf 
life.38 Trans fat has stability during deep-frying, and a 
“semisolid[]” consistency which, “can be customized to enhance the 
palatability of baked goods and sweets.”39 Artificially produced 
trans fat makes up about two to three percent of a consumers “total 
calories consumed.”40 Naturally occurring trans fat, makes up 
around 0.5 percent of total caloric intake for the average 
consumer.41 The drawback of trans fat comes from the health risks 
associated with the product.42  
Many private and government studies “suggest a link between 
trans fat consumption and serious, negative health effects such as 
heart disease, diabetes and cancer.”43 One of the major heart 
health concerns is the increase of bad cholesterol from trans fat: 
The major risk posed by trans fats is that they raise low 
density lipoprotein (LDL or bad) cholesterol in the blood. 
An elevated LDL cholesterol increases the risk of 
                                                                                                     
 36. See Dariush Mozaffarian et al., Trans Fatty Acids and Cardiovascular 
Disease, 354 NEW ENG. J. MED. 1601 (2006) (explaining the properties of trans 
fat). 
 37. See Christopher L. Burrell, Note, Co-Signing Danger: Why the FDA 
Should Tighten Regulations on the Use of Trans Fat in Foods in Order To Limit 
Its Adverse Effects on the Health of Low-Income African-Americans, 3 S. REGIONAL 
BLACK L. STUDENTS ASS’N L.J. 1, 1 (2009) (“Trans fat has proven to be cost 
effective, as it increases the shelf life of products and decreases the need for 
refrigeration.”). 
 38. Chacanaca v. Quaker Oats Co., 752 F. Supp. 2d 1111, 1115 (N.D. Cal. 
2010). 
 39. Mozaffarian, supra note 36, at 1601.   
 40. Id.  
 41. Id.  
 42. See Chacanaca, 752 F. Supp. 2d at 1115 (citing studies proffered by the 
plaintiff which support a link between consumption of trans fat and negative 
health consequences). 
 43.  Id. 
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developing coronary heart disease (CHD). Trans fat also 
lowers HDL-C [high-density lipoprotein or good 
cholesterol] and impair[s] FMD [flowed-mediated 
vasodilation]. This suggests that [trans fats] increase the 
risk of CHD more than the intake of saturated fats, with 
similar effects on LDL cholesterol.44 
Some countries have gone as far as restricting the use of trans fat 
in food products.45 As many as five European countries are on the 
road to banning trans fat through regulations, while many more 
have scaled back their consumption using self-regulatory 
mechanisms.46  
In 2013, the FDA made a determination that these partially 
hydrogenated oils were no longer generally recognized as safe for 
any use in human food.47 The FDA only now claims that it has 
taken steps to remove artificial trans fat from processed food 
entirely, within the next three years.48 This three year “compliance 
period” began in June 2015.49 Even with these new regulations, 
trans fat will still make its way into our diet.50 The FDA admits 
that trans fat will not be completely gone, “because [trans fat] also 
occurs naturally in meat and dairy products.”51 Companies can 
also petition the FDA for trans fat exemptions for specific uses.52  
                                                                                                     
 44. Andrew J. VanLandingham, The Awful Taste of Partially Hydrogenated 
Vegetable Oil: A Recommendation That Indiana Ban Trans Fats from 
Restaurants, 6 IND. HEALTH L. REV. 325, 330 (2009) (internal quotations omitted). 
 45. See Chacanaca v. Quaker Oats Co., 752 F. Supp. 2d 1111, 1115 (N.D. Cal. 
2010) (accepting plaintiff’s assertion that certain nations throughout the world 
have restricted or banned the use of products with trans fat). 
 46. See Europe Leads the World in Eliminating Trans Fat, WORLD HEALTH 
ORG., http://www.euro.who.int/en/media-centre/sections/press-
releases/2014/europe-leads-the-world-in-eliminating-trans-fats (last visited Apr. 
18, 2017) (“Denmark, Austria, Hungary, Iceland, Norway and Switzerland have 
set similar limits that virtually ban trans fats from food products, but 
consumption remains high where no policies are in place”) (on file with the 
Washington and Lee Journal of Civil Rights and Social Justice). 
 47. FDA Cuts Trans Fat in Processed Foods, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm372915.htm (last 
visited Apr. 18, 2017) (on file with the Washington and Lee Journal of Civil Rights 
and Social Justice) (emphasis added). 
 48. Id.  
 49. Id.  
 50. Id.  
 51. Id.  
 52. Id.  
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Trans fat bans on local levels have had a positive health 
impact.53 In 2007, New York City forced restaurants to stop using 
partially hydrogenated oils.54 A study in 2012 examined lunch 
receipts, collected from fast-food chains before and after the ban 
went into effect, and trans fat consumption dropped by 2.5 grams 
per meal.55 
From a policy standpoint, it has been argued that poor 
African-Americans are impacted at a greater rate by trans fat 
“because African-Americans are more likely than other 
populations to rely on cheaper food produced through unhealthy 
processing methods.”56 One example of how poor African-
Americans are more vulnerable to unhealthy food can be seen in 
the disbursement of fast-food restaurants in lower-income 
neighborhoods.57 This bears “a direct correlation to higher 
incidence of obesity.”58 Trans fat also impacts this community 
disproportionately in the following ways: 
Conditions such as hypertension, diabetes, and high cholesterol 
are widespread in the African-American community and are 
made worse by trans fat. When coupled with the fact that poor 
African-Americans may not understand nutrition labels, cannot 
afford higher priced products, and may live in fast food 
dominated neighborhoods, it becomes clear that they are 
particularly vulnerable to the effects of trans fat. Thus, greater 
measures are needed to better protect them as consumers.59 
                                                                                                     
 53. See Amanda MacMillan, NYC’s Fat Ban Paying Off, CNN (July 16, 2012), 
http://www.cnn.com/2012/07/16/health/nyc-fat-ban-paying-off (last visited Apr. 
18, 2017) (concluding that the reduced consumption due to the restrictions on 
trans fat is increasing the health of its citizens) (on file with the Washington and 
Lee Journal of Civil Rights and Social Justice). 
 54. Id. 
 55. Id. 
 56. Burrell, supra note 37. 
 57. See id. at 12 (describing a 2005 study that showed that 72% of the 
restaurants in South Los Angeles were fast food restaurants compared to only 
41% of restaurants in West Los Angeles, a more affluent neighborhood (citing 
ANNIE PARK ET AL., CMTY. HEALTH COUNCILS, SOUTH LOS ANGELES HEALTH EQUITY 
SCORECARD (2008))). 
 58. See id. (noting, from the same 2005 data, that 30% of South Los Angeles 
residents were obese compared to only 19.1% in the greater metropolitan area 
and only 14.1% in West Los Angeles). 
 59. Id. 
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B. Statutes & Regulations Involved in Trans Fat Labeling 
The Nutrition Labeling Education Act (NLEA), which 
amended the FDCA, was signed into law by President George H.W. 
Bush and allowed for greater regulation of nutritional claims.60 
The NLEA authorized the FDA to require ingredient disclosure.61 
Legislative history informs us that there were two distinct reasons 
for the NLEA. The first was to “establish uniform national 
standards for the nutritional claims and the required nutrient 
information displayed on food labels.”62 Second, the NLEA sought 
to ensure that any state law “requirement for nutrition labeling of 
foods that is not identical to the requirements” of the NLEA is 
preempted.63  
21 U.S.C. § 343 governs misbranded food.64 Under § 343(a)(1), 
a food product will be misbranded if “its labeling is false or 
misleading.”65 Together § 343(q) and § 343(r) “regulate the 
information that goes into the ‘nutrition box’ section on all 
packaged products [as well as] nutrient content claims that appear 
elsewhere on the label.”66 There is an important distinction 
between nutrient content claims and information that is declared 
on the nutrition label.67 “Information that is required or permitted 
to be declared in nutrition labeling, and that appears as part of the 
nutrition label, is not a nutrient content claim and is not subject” 
to the same requirements.68 When the information in the nutrition 
label is placed elsewhere on the item, it then becomes a nutrient 
content claim, which is subject to a different set of regulations.69 
The cases involved in the circuit split center mostly around 
                                                                                                     
 60. Pomeranz, supra note 12, at 422. 
 61. See id. at 422–23 (explaining how the NLEA expanded the scope of the 
FDCA in relation to misleading labeling claims). 
 62. See H.R. Rep. No. 101-538, at 12 (1990) (explaining the reasons the 
NLEA was authorized). 
 63. Id. at 8. 
 64. 21 U.S.C. § 343 (2012). 
 65. 21 U.S.C. § 343(a)(1) (2012). 
 66. Chacanaca v. Quaker Oats Co., 752 F. Supp. 2d 1111, 1117 (N.D. Cal. 
2010). 
 67. 21 C.F.R. § 101.13(c) (2016). 
 68. Id.  
 69. Id.  
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nutrient content claims that appear outside of the nutritional 
label.70  
An express nutrient content claim is a claim that makes a 
“direct statement about the level (or range) of a nutrient in the 
food, e.g., ‘low sodium’ or ‘contains 100 calories.’”71 An implied 
nutrient content claim indirectly describes the contents of a 
product and can occur in one of two ways.72 The first is when a 
claim “[d]escribes the food or an ingredient therein in a manner 
that suggests that a nutrient is absent or present in a certain 
amount (e.g., ‘high in oat bran’).”73 The second way is when a claim 
“[s]uggests that the food, because of its nutrient content, may be 
useful in maintaining healthy dietary practices and is made in 
association with an explicit claim or statement about a nutrient 
(e.g., ‘healthy, contains 3 grams (g) of fat’).”74  
Federal regulations state these nutrient content claims cannot 
be made on a products label, unless they are in accordance with 
governing regulations.75 For example, a nutrient content claim 
cannot be two times the size of the product’s statement of 
identity.76 A product’s statement of identity is the common or usual 
name for the product, such as “milk” on a milk carton.77 See Figure 
1 below for an example of Benecol’s nutrient content claim.78 On 
the bottom left of the front of the label there is a symbol of a heart, 
and the words, “NO TRANS FAT” are placed above the heart.79 
                                                                                                     
 70. See Young v. Johnson & Johnson, 525 F. App’x 179, 180–81 (3d Cir. 2013) 
(describing two claims made outside of the nutrition box). 
 71. 21 C.F.R. § 101.13(a)–(b) (2016).  
 72. See id. § 101.13(b) (“A claim that expressly or implicitly characterizes the 
level of a nutrient of the type required to be in nutrition labeling under 101.9 or 
under 101.36 . . . may not be made on the label or in labeling of the food. . . .”). 
 73. Id.  
 74. Id. (emphasis added). 
 75. Id. 
 76. See id. § 101.13(f) (“A nutrient content claim shall be in type size no 
larger than two times the statement of identity and shall not be unduly prominent 
in type style compared to the statement of identity.”).  
 77. See 21 C.F.R. § 101.3 (2016) (providing information on food packaging 
labels). 
 78. Benecol 55% Vegetable Oil Spread, GIANT EAGLE, 
http://www.gianteagle.com/300450839183.aspx (last visited Apr. 18, 2017) (on file 
with the Washington and Lee Journal of Civil Rights and Social Justice). 
 79. Id. 
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Figure 180 
C. Federal Preemption of Trans Fat Labeling Regulations 
Federal preemption of state laws dates back to the early 
history of the United States.81 Federal laws reign supreme over 
those of the states in certain situations due to the Supremacy 
                                                                                                     
 80. Id. 
 81. See M'Culloch v. Maryland, 17 U.S. 316, 427 (1819) (“It is of the very 
essence of supremacy, to remove all obstacles to its action within its own sphere, 
and so to modify every power vested in subordinate governments, as to exempt 
its own operations from their own influence.”). 
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Clause.82 Preemption occurs when, “(1) Congress enacts a statute 
that explicitly preempts state law; (2) state law actually conflicts 
with federal law; or (3) federal law occupies a legislative field to 
such an extent that it is reasonable to conclude that Congress left 
no room for state regulation in that field.”83 In areas of traditional 
state regulation there is a presumption against preemption unless 
Congress has clearly manifested its intent to do so.84  
The reason federal preemption is a recurring issue in these 
cases is because of the way that Congress amended the FDCA.85 
The NLEA added a preemption provision to the FDCA which 
expressly preempts “state laws addressing certain subjects 
[including labeling requirements] that are ‘not identical to’ various 
standards set forth by the FDCA . . . .”86 Federal preemption is an 
affirmative defense in these cases.87 The Defendants attempt to 
show that “an FDCA regulation [or NLEA amendment] governs 
the labeling claim.”88  
However, claims will not be preempted if the regulation is not 
found to govern trans fat.89 In Reid, the Ninth Circuit said to this 
point, “[i]t would be incongruous to have the same rule for both ‘No 
Fat’ . . . and ‘No Trans Fat’ claims, as the former is expressly 
permitted while the latter is not due to a lack of scientific 
consensus about the dangers of trans fat.90  
                                                                                                     
 82. U.S. CONST. art. VI, cl. 2. 
 83. Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947). 
 84. See Bates v. Dow Agrosciences LLC, 544 U.S. 431, 449 (2005) (“Congress 
added the remainder of the provision is evidence of its intent to draw a distinction 
between state labeling requirements that are pre-empted and those that are 
not.”). 
 85. See Lam v. Gen. Mills, Inc., 859 F. Supp. 2d 1097, 1102 (N.D. Cal. 2012) 
(discussing the FDCA and the NLEA). 
 86. Id. 
 87. See Trazo v. Nestle USA, Inc., No. 5:12-CV-2272 PSG, 2013 WL 4083218, 
at *6 (N.D. Cal. Aug. 9, 2013) (“It is imperative to note, however, that preemption 
is an affirmative defense, not an element of Plaintiffs’ claims”), reconsideration 
granted, No. 5:12-CV-02272-PSG, 2015 WL 4196973 (N.D. Cal. July 10, 2015). 
 88. Id. 
 89. See generally Reid v. Johnson & Johnson, 780 F.3d 952, 963 (9th Cir. 
2015).  
 90. See id. (“Thus, the FDA’s reading of section 101.13(i)(3)—that the 
regulation does not authorize ‘No Trans Fat’ claims—makes the most sense of the 
overall labeling regime . . . .”). 
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III. Analysis of the Circuit Split between the Ninth and 
Third Circuit 
A. Ninth Circuit Decisions 
In 2012, Carrea v. Dreyer’s Grand Ice Cream, Inc.91 was 
decided by the Ninth Circuit.92 Carrea involved a consumer 
protection claim surrounding a manufacturer’s product that stated 
it contained “0 g Trans Fat.”93 Importantly, a “premium price” was 
charged for the product, above that of similar products.94 The 
Plaintiff claimed he was only willing to pay that premium price 
because he believed the higher priced products were better than 
other frozen dessert products due to the alleged 
misrepresentations.95  
The District Court decided these allegations satisfied the 
injury-in-fact requirement necessary to pursue claims under 
California’s Unfair Competition Law (UCL),96 False Advertising 
Law (FAL),97 and the California Consumer Legal Remedies Act 
(CLRA).98 The UCL states that: “unfair competition shall mean 
and include any unlawful, unfair or fraudulent business act or 
practice and unfair, deceptive, untrue or misleading 
advertising . . . .”99 The FAL states it is unlawful to make any 
statement “which [is] untrue or misleading, and which is known, 
or which by the exercise of reasonable care should be known, to be 
untrue or misleading . . . with the intent not to sell that personal 
                                                                                                     
 91. 475 F. App’x 113 (9th Cir. 2012). 
 92. Id. 
 93. See Carrea v. Dreyer’s Grand Ice Cream, Inc., No. C 10-01044 JSW, 2011 
WL 159380, at *2 (N.D. Cal. Jan. 10, 2011) (describing the allegation that 
Defendant charges a premium price for its ice cream products based on 
“misrepresentations that they contain original ingredients and zero grams of 
trans fat.”). 
 94. Id. 
 95. See id. (explaining Plaintiff’s argument that Defendant charged a 
premium price based on a misrepresentation, satisfying an injury in fact 
requirement showing grounds for possible standing). 
 96. CAL. BUS. & PROF. CODE § 17200 (West 2016). 
 97. CAL. BUS. & PROF. CODE § 17500 (West 2016). 
 98. CAL. CIV. CODE § 1750 (West 2016). 
 99. CAL. BUS. & PROF. CODE § 17200 (West 2016). 
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property or those services . . . as so advertised.”100 The CLRA 
includes a list of twenty plus proscribed practices, one of which is 
“[u]sing deceptive representations”.101  
The Defendant in Carrea challenged the claims made under 
state law on the premise that they impose requirements that are 
“’not identical to’ the requirements set forth in regulations 
promulgated by the Food and Drug Administration . . . and are 
therefore expressly preempted pursuant to the Federal Food, Drug 
and Cosmetic Act . . . as amended by the Nutrition Labeling and 
Education Act . . . .”102 The regulation at issue expressly requires 
that “if the serving contains less than 0.5 gram, the content, when 
declared, shall be expressed as zero.”103 The Defendant reasoned 
that “a statement about the amount or percentage of a nutrient [is 
permitted] if [t]he statement does not in any way implicitly 
characterize the level of the nutrient in the food and it is not false 
or misleading in any respect . . . .”104  
District Judge Jeffrey S. White, who wrote the opinion in 
Carrea, first discussed recent decisions that involved preemption 
due to the federal regulatory statute.105 Specifically he focused on 
Chacanaca, which involved the labeling of granola bars that 
contained “0 Grams Trans Fat” statements.106 Judge White was 
building a foundation to ultimately declare Carrea’s claims were 
preempted and reminded the parties that “[i]n Chacanaca, the 
Court determined that [federal regulations did] preempt . . . state 
or local governments from imposing any requirement on nutrient 
content claims . . . not identical to the requirement of section 
343(r).”107 Title 21 U.S.C. § 343(r) governs nutrient content claims 
that manufacturers choose to include on a “food label or package, 
                                                                                                     
 100. CAL. BUS. & PROF. CODE § 17500 (West 2016). 
 101. CAL. CIV. CODE § 1770 (West 2016); CAL. CIV. CODE § 1750 (West 2016). 
 102. Carrea v. Dreyer’s Grand Ice Cream, Inc., No. C 10-01044 JSW, 2011 WL 
159380, at *3 (N.D. Cal. Jan. 10, 2011). 
 103. 21 C.F.R. § 101.9(c)(2) (2016). 
 104. Carrea, 2011 WL 159380, at *3 (internal quotations omitted). 
 105. See id. (“Several recent District Court decisions have held that claims 
based on statements concerning nutrient content, or using terms that the FA has 
defined or permitted, are preempted by the federal statute.”). 
 106. See id. at *4 (explaining that the court in Chacanaca preempted any 
state or local government from imposing nutrient content claims requirements 
made by food purveyors). 
 107. Id. (internal citations omitted) (emphasis added). 
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that is, a claim that expressly or by implication . . . characterizes 
the relationship of any nutrient required by [section 343(q)(1) or 
(2)] to be in the label.”108 An accompanying regulation provides 
that “[i]f such information is declared [outside of the nutrition 
label] . . . it is a nutrient content claim and is subject to the 
requirements for nutrient content claims.”109At the District Court 
level in Carrea, the Chacanaca preemption reasoning cited by 
Judge White above won the day.110  
In 2012, the Ninth Circuit affirmed the judgment of the 
district court in Carrea.111 The court found that the Plaintiff’s 
claims regarding the “0g Trans Fat” statement were expressly 
preempted by the FDCA as amended by the NLEA. 112 The Court 
decided that the statement was “an express nutrient content claim 
that the [FDA] not only permits . . . but further instructs should 
mirror the Nutrition Facts panel.” 113 
On March 13, 2015, the Ninth Circuit, in Reid v. Johnson & 
Johnson,114 reversed a district court decision and ruled that a class 
action group of consumers were not preempted by the NLEA in 
their claims that the manufacturer’s vegetable oil based spread 
contained misrepresentations in violation of California’s unfair 
competition law, false advertising law, and consumer legal 
remedies act.115 This decision in March 2015 created the circuit 
split between the Ninth and Third Circuit. The history of Reid is 
important to understanding how the Ninth Circuit changed its 
opinion on the preemption of these claims.116  
                                                                                                     
 108. Id. (internal citations omitted). 
 109. Id. at *4 (internal citations omitted) (emphasis added). 
 110. See Carrea v. Dreyer’s Grand Ice Cream, Inc., No. C 10-01044 JSW, 2011 
WL 159380, at *4 (N.D. Cal. Jan. 10, 2011) (“Adopting the reasoning of 
Chacanaca, the Court concludes that the ‘0g Trans Fat’ statement on Defendant’s 
Drumsticks packaging, outside the Nutrition Facts box, is a nutrient content 
claim subject to the express preemption provision of the NLEA.”). 
 111. Carrea v. Dreyer’s Grand Ice Cream, Inc., 475 F. App’x 113, 115 (9th Cir. 
2012). 
 112. Id. 
 113. Id. (internal citations omitted). 
 114. 780 F.3d 952 (9th Cir. 2015). 
 115. Id. at 963. 
 116. See Reid v. Johnson & Johnson, No. 11CV1310 L BLM, 2012 WL 
4108114, at *1 (S.D. Cal. Sept. 18, 2012) (discussing the defendant’s product and 
the reason for plaintiff’s claim). 
AN EXAMINATION OF TRANS FAT LABELING 477 
The defendants in Reid, Johnson & Johnson, and its 
subsidiary, McNeil Nutritionals, LLC, manufacture a product 
called Benecol.117 Benecol’s website claims “Our spreads are ideal 
substitutes for traditional butter and margarines.”118 The 
vegetable-oil-based spread has the following statements on its 
labels: “Proven to Reduce Cholesterol; No Trans Fat; No Trans 
Fatty Acids.”119 The Plaintiff contended that these claims were 
false because Benecol actually contains small amounts of trans 
fat.120 The Plaintiff also claimed the product was misbranded 
because it contained unauthorized nutrient content claims.121  
The District Court reasoned that the Plaintiff was merely 
seeking to distinguish, “No Trans Fat” and “No Trans Fatty Acids” 
on the Benecol packaging from “0g trans fat” or “0 grams trans fat” 
seen in Carrea, where the consumers’ claims were dismissed.122 
The District Court did not agree that this distinction should result 
in a different outcome than Carrea, calling it unreasonable and 
thus finding the trans fat claims expressly preempted by the 
NLEA.123 
On appeal, the Ninth Circuit approached the question in Reid 
by establishing the determination of the Plaintiff’s “No Trans Fat” 
claim would turn on whether the statement is authorized by FDA 
regulations governing express nutrient claims.124 The court first 
determined that the trans fat statements on the Benecol packaging 
were express claims because they were direct statements about the 
                                                                                                     
 117. Id. 
 118. See Our Food Range, BENECOL, http://www.benecol.ie/web/benecol.ie/ 
our-food-range/spreads (last visited Apr. 18, 2017) (detailing the variety of 
spreads available as alternatives to butter or margarine) (on file with the 
Washington and Lee Journal of Civil Rights and Social Justice). 
 119. Reid, 2012 WL 4108114, at *1. 
 120. Id. 
 121. Id. 
 122. See id. at *10 (“[P]laintiff is attempting to distinguish ‘0g trans fat’ or ‘0 
grams trans fat’, which the FDA permits under 21 C.F.R. § 101.13(i)(3), with 
Defendants’ labeled Benecol’s trans fat content, ‘No Trans Fat’ and ‘No Trans 
Fatty Acids’, thereby avoiding express preemption.”). 
 123. See id. (“Accordingly, the Court finds that Plaintiff’s trans fat claims are 
expressly preempted by the NLEA.”). 
 124. See Reid v. Johnson & Johnson, 780 F.3d 952, 962 (9th Cir. 2015) (“The 
preemption analysis of the ‘No Trans Fat’ claim turns on whether the statement 
is authorized by FDA regulations.”). 
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amount of trans fat in the product.125 The court reasoned that FDA 
regulations would only allow express claims that “do not in any 
way implicitly characterize the level of the nutrient in the food and 
[are] not false or misleading in any respect.”126  
In deciding if these claims were authorized and thus 
preempted, the court turned its focus to warning letters issued by 
the FDA.127 Specifically, the court examined the guidance that the 
FDA has given on whether a “No Trans Fat” nutrient content claim 
is allowed when products actually contain small amounts of trans 
fat.128 The first letter stated, “‘No Trans Fat’ is ‘an unauthorized 
nutrient content claim.’”129 Next, the court noted that a second 
letter from the FDA specifically stated “trans fat-free” is an 
“unauthorized nutrient content claim.”130  
Regarding the binding impact of those letters, the court noted 
they are only one of many enforcement measures the FDA uses to 
police labels, but ultimately are merely informal and advisory.131 
The FDA uses these letters to try and obtain voluntary changes 
from manufactures, with what it considers to be violations of the 
FDCA or NLEA.132 The Ninth Circuit further stated that these 
letters or agency interpretations, whether informal or not, should 
be controlling unless they are clearly erroneous.133 Following that 
principle, and believing the letters were not clearly erroneous, the 
Ninth Circuit chose to defer to the FDA’s interpretation that the 
claims on the packaging were not allowed and thus the Plaintiff’s 
claims were not preempted.134 An additional reason for the Ninth 
Circuit’s decision on the preemption issue was that, “[a] nutrient 
                                                                                                     
 125. Id. 
 126. Id. 
 127. See id. (“The FDA has provided guidance about whether a ‘No Trans Fat’ 
nutrient content claim is permissible for products containing small amounts of 
trans fat.”). 
 128. Id. 
 129. Id. 
 130. Id. 
 131. Id. at 962 n.5. 
 132. Id.  
 133. See Auer v. Robbins, 519 U.S. 452, 461 (1997) (explaining how the court 
gives deference to the Secretary of Labor’s interpretation unless it is deemed 
clearly erroneous). 
 134. Reid v. Johnson & Johnson, 780 F.3d 952, 962–63 (9th Cir. 2015). 
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content claim fails if it is false or misleading in any respect. 
Because Benecol contains some trans fat (between 0 and 0.5 grams 
per serving), its ‘No Trans Fat’ claim is misleading in at least one 
respect.”135  
The structure and language of FDA labeling regulations 
reinforce the Ninth Circuit’s conclusion that the Plaintiff’s claims 
should not be preempted.136 The FDA expressly allows “‘No Fat’ 
and ‘No Saturated Fat’ claims for products that contain less than 
0.5 grams of fat or saturated fat per serving.” On the other hand, 
“No Trans Fat” claims were given the opposite treatment, and not 
authorized due to a lack of scientific information.137  
The Ninth Circuit reasoned “if section 101.13(i)(3) authorizes 
‘No Fat’ and ‘No Saturated Fat’ claims for products with small 
amounts of fat or saturated fat, then why would the FDA go to the 
trouble of promulgating a separate regulation expressly allowing 
these claims?”138 The Defendant’s interpretation would make 
several regulations redundant.139 It would be inconsistent logic by 
the FDA to have the same regulation for Fat and Trans Fat claims 
because fat claims are expressly permitted, while trans fat claims 
are not permitted due to the lack of a consensus about potential 
dangers of trans fat.140 “Thus, the FDA’s reading of section 
101.13(i)(3)—that the regulation does not authorize ‘No Trans Fat’ 
[statements]—makes the most sense of the overall labeling 
regime . . . .”141 Accordingly, the claims should not be preempted.  
The Ninth Circuit rejected several of the Defendant’s 
arguments in Reid. The first theory rejected was that the “No 
Trans Fat” statement outside of the nutritional label is the 
equivalent of the 0 grams of trans fat per serving statement inside 
the nutritional label.142 The second theory was that the FDA allows 
for reasonable synonyms of authorized nutrient content claims to 
                                                                                                     
 135. Id. at 962. 
 136. See id. (“The structure of FDA labeling regulations bolsters this 
conclusion.”). 
 137. Id. 
 138. Id. at 963. 
 139. Id. 
 140. Id. at 962–63. 
 141. See id. at 963 (explaining this would give meaning to 21 C.F.R. 
§ 101.62(b)-(c) (2016)). 
 142. Id. 
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be placed on the label, as long as they are not misleading.143 The 
Defendant argued that the “No Trans Fat” claim was a reasonable 
synonym.144 The court refuted that argument by calling attention 
to the fact that claims “like Benecol's ‘0 grams trans fat per serving’ 
claim [on the nutrition label], are not nutrient content claims and 
thus are not covered by [the] synonym rule.”145 The fact that 
Benecol must state that it contains “0 grams of trans fat per 
serving on its nutrition label makes no difference here” because the 
nutrient content claims are at issue, not the nutritional label.146 
B. Third Circuit Decisions 
In 2013, the Third Circuit in Young decided consumer class 
action claims regarding trans fat nutrient content claims in 
Benecol were preempted.147 Young involved the same product that 
was later at issue in the Reid case. At the District Court level in 
Young the Plaintiff claimed that Benecol’s “No Trans Fatty Acids” 
representations outside of the label were false and misleading as 
the product contains small amounts of trans fat.148 The Plaintiff 
filed a complaint that included: violations of the New Jersey 
Consumer Fraud Act, breach of express warranties, breach of the 
implied covenant of merchantability, and unjust enrichment.149 
Johnson & Johnson’s motion to dismiss was granted by the District 
Court.150  
                                                                                                     
 143. See 21 C.F.R. § 101.13(b)(4) (2016) (“Reasonable variations in the 
spelling of the terms defined in part 101 and their synonyms are permitted 
provided these variations are not misleading.”). 
 144. See Reid v. Johnson & Johnson, 780 F.3d 952, 962–63 (9th Cir. 2015) 
(discussing how a reasonable consumer would read the nutrient content claim).  
 145. Id. at 963. 
 146. See id. (explaining that required nutrition label claims can differ from 
nutrition content claims). 
 147. See Young v. Johnson & Johnson, 525 F. App’x 179, 183–85 (3d Cir. 2013) 
(stating that Young’s theories of liability were preempted and properly 
dismissed).   
 148. See id. at 181 (listing the five-count complaint allegations). 
 149. Id. 
 150. See id. (stating that the District Court concluded that Young lacked 
standing and Young’s claims were preempted).  
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The two issues on which the court decided the motion to 
dismiss were standing and preemption.151 In order to satisfy the 
constitutional minimum of standing, three elements must be 
established by the plaintiff.152 First, the plaintiff must have 
suffered an “injury in fact.”153 Injury in fact is defined as an 
invasion of a legally protected interest which is “concrete and 
particularized” and “actual or imminent,” not “conjectural or 
hypothetical.”154 The second element is a causal connection 
between the injury in fact and the conduct complained of.155 Last, 
the injury must be “likely, as opposed to merely speculative” that 
the injury will be redressed by a decision in favor of the plaintiff.156  
In Young the Plaintiff did not claim that he suffered any 
adverse health problems from Benecol.157 In fact, Plaintiff did not 
claim that he consumed the product, but did claim he purchased 
the product regularly over a “five-year period” of time.158 Plaintiff’s 
injury in fact was not satisfied in the eyes of the court because it 
was determined to be an “apprehension about possible future 
injury.”159 For these reasons, the District Court determined the 
Plaintiff lacked standing as injury-in-fact was not “adequately 
pled.”160 
Another important factor in the eyes of the District Court was 
that Benecol’s packaging did contain a disclosure regarding 
partially hydrogenated oils and trans fat.161 Thus, the substance of 
Plaintiff’s complaint, which stated that Benecol’s health claims 
were “false and misleading,” were arguably disclosed to him. The 
disclosure stated in part, a small amount of “partially 
                                                                                                     
 151. Id.  
 152. See Lujan v. Defenders of Wildlife, 504 U.S. 555, 560–61 (1992) (listing 
how courts have defined the requirement for establishing standing). 
 153. See id. at 560 (citing Allen v. Wright, 468 U.S. 737, 757 (1984)). 
 154. Id. 
 155. Id. 
 156. Id. 
 157. See Young v. Johnson & Johnson, No. CIV.A. 11-4580 JAP, 2012 WL 
1372286, at *2–*5 (D.N.J. Apr. 19, 2012) (stating that adverse health conditions 
may help demonstrate an injury-in-fact). 
 158. Id. 
 159. Id. 
 160. Young v. Johnson & Johnson, 525 F. App’x 179, 181 (3d Cir. 2013). 
 161. See Young, 2012 WL 1372286, at *4 (discussing the importance of 
disclosure while analyzing the injury-in-fact claim element). 
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hydrogenated oils are used in Benecol . . . . As a result, Benecol 
Spreads, contain an extremely low level of trans fat. The FDA 
allows foods containing less than 0.5 grams of trans fat/serving to 
be labeled 0 grams trans fat, since this is considered an 
insignificant amount.”162 With regards to the preemption issue, the 
District Court concluded quickly that Plaintiff's claims regarding 
Benecol’s statements were expressly preempted because they 
sought to impose requirements that were “inconsistent” with 
federal law.163 
On appeal, the Court of Appeals granted Young’s standing as 
“tenuous” but decided to fully consider the case.164 On the merits, 
Young’s claims against Johnson & Johnson, were again 
determined to be expressly preempted by the Food, Drug and 
Cosmetic Act as amended by the Nutrition Labeling and Education 
Act.165 “The NLEA expressly preempts any state-imposed 
requirement for nutrition labeling of food, or with respect to 
nutritional or health-related claims, ‘that [are] not identical to the 
requirement’ set forth in the relevant provisions of the Act.”166 
Young did not challenge that principle, but instead claimed his 
state law causes of action regarding Johnson & Johnson’s alleged 
misrepresentations are not preempted because they are identical 
to those set forth in the NLEA.167 
Young maintained that “although the regulations authorize 
Benecol to claim that it contains ‘0g of Trans Fat Per Serving,’ they 
do not expressly permit a claim of ‘NO TRANS FAT’ for the product 
as a whole.”168 Young made the distinction in his opening brief that 
he “seeks to prohibit false and misleading nutrient content claims 
regarding trans fat content per product. Prohibition of such 
                                                                                                     
 162. Id. at *8. 
 163. Id. at *15.  
 164. See Young, 525 F. App’x at 182 n.4 (stating that Young’s specific facts 
allowed the Court to review the merits). 
 165. Id. at 181. 
 166. Id. at 181–82. 
 167. See id. at 182 (arguing that the claims are identical to the NLEA, Young 
asserts that his product contains no trans fats and the product has been proven 
to reduce cholesterol). 
 168. Id. at 182. 
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statements is not inconsistent with the FDA's regulation allowing 
nutrient content claims about trans fat per serving.”169  
To further understand Young’s argument, below is a brief 
overview of the FDA’s own opinion on nutrient content claims per 
product versus per serving. First the FDA says that the distinction 
between nutrient content claims per product and per serving is 
necessary to understand and use the nutrition label correctly.170 
The FDA website explains the relationship between a serving size 
and the whole package.171 The explanation states, “[t]he size of the 
serving on the food package influences the number of calories and 
all the nutrient amounts listed on the top part of the label.”172 
Seeking to emphasize the distinction between a serving size in the 
entire product, the FDA website goes on to say: “Pay attention to 
the serving size, especially how many servings there are in the food 
package. Then ask yourself, ‘How many servings am I consuming’? 
(e.g., 1/2 serving, 1 serving, or more).”173 The FDA also provides a 
sample label on the website.174 The accompanying description 
states, “[i]n the sample label, one serving of macaroni and cheese 
equals one cup. If you ate the whole package, you would 
eat two cups. That doubles the calories and other nutrient 
numbers, including the %Daily Values as shown in the sample 
label.”175 While that example used calories, the logic would remain 
true for trans fat. Again, Young claims he sought to prohibit 
misleading manufacturer statements pertaining to per product 
representations, not trans fat statements per serving, which may 
or may not be permitted by the FDA. 
                                                                                                     
 169. See id. (citing Brief for Appellant, Opening Br. at 25). 
 170. See How To Understand and Use the Nutrition Facts Label, U.S. FOOD & 
DRUG ADMIN., 
http://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm2
74593.htm (last visited Apr. 18, 2017) (explaining that various factors help 
determine the Nutrient Content label) (on file with the Washington and Lee 
Journal of Civil Rights and Social Justice). 
 171. See id. (discussing how serving size labels attempt to help consumers 
understand how serving sizes and whole package sizes differ).  
 172. Id. 
 173. Id. 
 174. See id. (displaying a sample Nutrition Facts label and explaining how 
consumers can properly analyze these Nutrition labels).  
 175. Id. (emphasis in original). 
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See Figure 2 below for an example of a sample nutrition label 
with a red circle around where Trans Fat would have been 
indicated on these products. That number would then be 
multiplied by the number of servings, this product has thirty-two 
servings.  
Figure 2176 
Before rebutting Young’s allegations regarding per product 
claims, the Court of Appeals did admit that the FDA has 
recognized the potential for a consumer to misinterpret that a 
product is “free” of a nutrient such as trans fat, when a nutrient 
content claim of 0 grams per serving is made.177 In 1993, the FDA 
                                                                                                     
 176. See FDA Cuts Trans Fat in Processed Foods, supra note 47. 
(“A variety of processed foods—including frozen, canned and baked goods—
contain trans fat. The amount per serving is listed on the Nutrition Facts 
label . . . . The inclusion of partially hydrogenated oil in the list of ingredients is 
another indication [of] trans fat.”). 
 177. See Young v. Johnson & Johnson, 525 F. App’x 179, 183 (3d Cir. 2013) 
(stating that the requirement for disclosure may produce a potential for 
discrepancy) (emphasis added). 
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admitted that “[s]uch declarations could be confusing to 
consumers, and this consequence is unintended. ‘Free’ claims are 
different than claims such as ‘low,’ which do not create an 
expectation in consumers' minds that the food bearing the claim 
will possess a [specific] amount of the nutrient in question.”178 In 
an attempt to clear up this “misleading and confusing” labeling the 
FDA decided that “the determination of whether a product is free 
of a nutrient be based on the value of the nutrient . . . per labeled 
serving.”179 The court stated this decision was made in the interest 
of “clarity and consistency” and because of that decision “FDA 
regulations therefore authorize nutrient content claims based on 
per serving amounts, even if those claims are not entirely accurate 
on a per product basis.”180  
In support of this per serving position, the court examined 
three regulations governing other substances which authorize 
nutrient content claims that a food is “free” of a specific nutrient 
when it contains low levels.181 They include the authorization of 
nutrient content claims that a food is calorie free when it contains 
less than 5 calories per serving, claims that that a food is sodium 
free if it contains less than 5 milligrams of sodium per serving and 
claims that a food contains no fat or no saturated fat if it contains 
less than 0.5 grams per serving.182 Therefore, the court reasoned, 
“the ‘NO TRANS FAT’ claim on the Benecol label is not 
‘misleading’ as that term is used in [the regulation] and is 
authorized . . . even if a ‘no trans fat’ claim is not expressly 
contemplated by the regulations.”183  
In reaching the above decision the Third Circuit cited three 
cases which had reached a similar conclusion. All three of those 
cases were mentioned above, Carrea, Chacanaca, and Reid.184 
Interestingly the Third Circuit in Young cited the Reid decision 
from the lower court which was ultimately overturned in favor of 
                                                                                                     
 178. See Food Labeling: Nutrient Content Claims, General Principles, 
Petitions, Definition of Terms, 58 Fed. Reg. 44020, 44025 (Aug. 18, 1993) 
(discussing the unintended confusion from these declarations). 
 179. Id.  
 180. Young, 525 F. App’x at 183. 
 181. Id.  
 182. Id. 
 183. Id. 
 184. Id. 
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the Plaintiff, and it was decided his claims were not preempted, 
which brings the reasoning of the Third Circuit into question.185 
Two other cases relied on by the Third Circuit, Carrea and 
Chacanaca, were also Ninth Circuit cases decided before the 2015 
Reid case which determined claims were not preempted. 
Nonetheless, the court concluded “[n]utrient content claim 
regulations promulgated under the NLEA thus authorize the 
Trans Fat Claims, based on the per serving amount of trans fats 
that the product contains.”186 The Court further reasoned 
“[b]ecause Young seeks to bar that disclosure under state law, in 
effect enforcing state law requirements that are not identical to the 
NLEA, his action is expressly preempted as it relates to those 
claims.”187 
C. Other Decisions Involving Trans Fat Misrepresentation 
The facts in the below cases do not exactly parallel those of the 
circuit split above, but the analysis sheds light on what might 
happen if these courts were to face an issue more similar to the 
circuit split.  
United States District Court, N.D. Illinois,  
Eastern Division 
Consumers claimed that The Quaker Oats Company lured 
consumers into buying their products by “touting them as being 
(among other things) ‘wholesome’ and ‘heart healthy,’ when in 
reality the products contain unhealthy trans fats.” 188 Plaintiff 
claimed that these products were misleading because its packaging 
and marketing campaigns both state the product contains 0 grams 
of trans fat.189 The product actually contained up to 5 grams of 
trans fat per box.190 The central issue in this decision was whether 
the consumers had established standing.191 The court held that the 
                                                                                                     
 185. Id.  
 186. Id.  
 187. Id. 
 188. Id. at 1083.  
 189. Id. at 1083.  
 190. Id. 
 191. Id. 
AN EXAMINATION OF TRANS FAT LABELING 487 
injury-in-fact requirement was established because the consumers 
paid more for these products than they would have, had they 
known they were being subjected to health risks.192  
Quaker argued that because the consumers were not 
physically harmed by the allegedly misleading product, they 
lacked standing.193 The court decided to follow a recent Seventh 
Circuit decision, which stated that a lack of a physical harm to the 
consumers does not mean that they lack standing, as financial 
injury can create standing. “The plaintiffs’ loss is financial: they 
paid more for the [the product] than they would have, had they 
known of the risks [product] posed to [them].”194 The court 
determined the consumers’ claims were supportable due to the 
allegedly misleading product packaging regarding the absence of 
trans fat.195 
Immediate Consumption 
Products that were ready for immediate consumption also 
created diverging opinions about whether claims were 
supportable. McDonald’s publishes the fat and calorie contents of 
its products; this information is available in store and on the 
company’s website.196 Prior to February 8, 2006, McDonald’s stated 
that its large fries contained six grams of trans fat.197 On February 
8, 2006, McDonald’s changed its position and stated that the large 
fries actually contained eight grams of trans fat.198 Plaintiff 
consumers in Reyes maintained that they knew about the 
McDonald’s representations prior to February 8, and claimed they 
would have modified their McDonald’s fries consumption had they 
known the correct information.199 In order to state a claim under 
the Illinois Consumer Fraud and Deceptive Practices Act, the 
                                                                                                     
 192. Id. 
 193. Id. at 1084. 
 194. See id. (quoting In re Aqua Dots Prod. Liab. Litig., 654 F.3d 748, 751 (7th 
Cir. 2011)). 
 195. Id. 
 196. See Reyes v. McDonald’s Corp., No. 06 C 1604, 2006 WL 3253579, at *1 
(N.D. Ill. Nov. 8, 2006) (describing the ways that McDonald’s made nutrition 
information available to the public). 
 197. Id. 
 198. Id. 
 199. Id. 
488 23 WASH. & LEE J. CIVIL RTS. & SOC. JUST. 461 (2017) 
Plaintiffs must allege that “(1) McDonald's is engaged in a 
deceptive act or practice; (2) McDonald's intended that Plaintiffs 
would rely on the deception; (3) the deception occurred in the 
course of conduct involving trade and commerce; (4) Plaintiffs were 
injured; and (5) conduct proximately caused Plaintiffs' injury.”200 
In Reyes the court ultimately determined that the Plaintiffs had 
pled the elements sufficiently enough to survive a motion to 
dismiss.201 
In 2007, the United States District Court for the District of 
Columbia dismissed a physician’s action against Yum! Brands, Inc. 
where the physician claimed that KFC failed to reveal its use of 
trans fat, holding that the physician did not state a claim 
supported under any legal theory.202 The physician stated in his 
complaint that “KFC’s use of partially hydrogenated oil is 
‘unnecessary,’ because healthier oils were available. KFC 
advertises on its website that KFC products are part of a 
nutritionally healthy lifestyle. The advertisements do not reveal 
the use of trans fats.”203 Additionally, the Plaintiff stated that 
because of the FDA’s warnings about trans fat in 2004 and 2005, 
he was trying to avoid trans fat, but KFC did not display any 
warning about its food containing trans fat.204 In its examination 
of Plaintiff’s allegations, the court found the Plaintiff did not allege 
that he had suffered any immediate ill effects, nor any other kind 
of injury from the food he consumed.205 After finding that the 
Plaintiff failed to allege any kind of injury, the court determined 
that Plaintiff lacked standing in this action.206 The court stated 
that the Plaintiff did plead economic injury but “[did] not specify 
what ‘economic injury’ he has suffered, and none is evident from 
the facts presented, even under the most charitable reading of the 
complaint.”207  
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The Court’s statement about a possible economic injury is 
significant in that it suggests it may grant standing if the same 
scenario was brought before it again.208 If this Plaintiff were to 
claim that he paid a higher price for KFC over other fast foods, the 
outcome may have been different.  
IV. Conclusion 
There are four compelling reasons why the Ninth Circuit’s 
interpretation is the correct one. First, the warning letters issued 
by the FDA plainly state that “No Trans Fat” is an unauthorized 
nutrient content claim. The letters are not binding, but the Ninth 
Circuit determined they were not clearly erroneous, and thus 
history dictates they should be followed. Second, the cases relied 
on by the Third Circuit in Young bring the foundation of their 
analysis into question. The Third Circuit cited three Ninth Circuit 
cases for the proposition that claims should be preempted. One of 
the cases the Third Circuit relied on was the lower court’s decision 
in Reid, which was overturned in 2015, stating claims are not 
preempted. The other two cases, Carrea and Chacanaca, were 
decided before the 2015 Reid decision. In fact, The Quaker Oats 
Company paid $1.4 million to settle the formerly named 
Chacanaca class action in 2014.209 Third, the structure of FDA 
labeling regulations show that the Defendant’s interpretation 
would make several regulations redundant. As mentioned above, 
it would be inconsistent for the FDA to use the same regulation for 
Fat and Trans Fat claims because those two substances have been 
given drastically different treatment. The reason these substances 
have been given different treatment is because of a lack of scientific 
information on trans fat.  
Fourth, the Third Circuit mistakenly strays from the 
simplicity that 21 U.S.C. § 343(a)(1) offers.210 Section 343(a)(1) 
states that a food product will be misbranded if its labeling is false 
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or misleading in any respect. Using that straightforward guideline, 
Benecol’s nutrient content claim of “No Trans Fat” is undoubtedly 
misleading because it contains trans fat. The Third Circuit cites 
calories, sodium, and fat as examples of substances where 
authorization was given to make nutrient content claims that a 
food is “free” of a substance, when it in fact does contain small 
amounts of it. What the Third Circuit fails to recognize is that 
trans fat is substantially worse for human health than those 
products, and has historically been treated differently than them. 
The FDA in 2013 made a determination that partially 
hydrogenated oils and trans fat were no longer generally 
recognized as safe for any use in human food.211 A substance given 
that distinction should not be treated the same as calories or fat.212 
The Ninth Circuit’s decision in Reid that nutrient content claims 
such as “No Trans Fat” were not authorized, and thus claims are 
not preempted under federal law, is the correct interpretation.  
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